CureVac N.V., a renowned biotech company specializing in messenger RNA (mRNA) technology for innovative medical solutions, has recently announced the amicable resolution of patent litigation with Pfizer/BioNTech. The resolution involves agreements between CureVac, an affiliate of GSK, BioNTech, and Pfizer to settle and dismiss all ongoing patent disputes in the United States regarding mRNA-based COVID-19 vaccines. Furthermore, a framework has been established to address any lingering patent conflicts outside the U.S. following BioNTech’s acquisition of CureVac, which was initially revealed on June 12, 2025.
As part of the settlement terms, CureVac and GSK are set to receive a combined payment of $740 million along with single-digit royalties on the sales of COVID-19 vaccines in the U.S. moving forward. Additionally, CureVac will be granted $50 million by GSK for the monetization of a portion of U.S. product royalties under their existing license agreement from July 3, 2024. Moreover, CureVac will provide BioNTech and Pfizer with a non-exclusive license to manufacture, use, import, and sell mRNA-based COVID-19 and/or influenza products. This license is anticipated to evolve into a global agreement upon the completion of BioNTech’s acquisition of CureVac.
Founded in 2000, CureVac has been at the forefront of mRNA technology advancement for medical applications, especially in the context of developing mRNA vaccines against COVID-19. The company’s expertise in mRNA technology, coupled with cutting-edge tools in omics and computational sciences, allows for the creation of off-the-shelf and personalized precision immunotherapy candidates for treating cancer and other unmet medical needs. CureVac’s operations span across various countries, including Germany, the Netherlands, Belgium, Switzerland, and the U.S., reflecting its commitment to pioneering medical innovation on a global scale.
The regulatory approval process for BioNTech’s acquisition of CureVac remains on track as per the announcement made in June 2025, underscoring the stability and continuity of the acquisition terms. This development signifies a significant milestone in the biotech industry, particularly in the realm of mRNA-based therapeutics and vaccines. The resolution of patent disputes between these key players in the field is poised to foster collaboration and propel advancements in mRNA technology, potentially leading to groundbreaking medical solutions in the future.
Key Takeaways:
– CureVac and GSK will receive $740 million and royalties for COVID-19 vaccine sales in the U.S. following the resolution of patent disputes with Pfizer/BioNTech.
– BioNTech and Pfizer will be granted a non-exclusive license by CureVac to produce and sell mRNA-based COVID-19 and influenza products, with a global license expected post BioNTech’s acquisition of CureVac.
– CureVac’s pioneering work in mRNA technology for medical applications positions it as a leader in developing innovative precision immunotherapy candidates for cancer treatment and other therapeutic areas.
– The resolution of patent litigation between CureVac, GSK, BioNTech, and Pfizer marks a significant step towards fostering collaboration and driving advancements in mRNA-based medical solutions.
Tags: regulatory, immunotherapy, biotech
Read more on medicaldialogues.in